Help
Subscribe


All of GastroHep is now free access! - Click here to register Read For FREE - Our full range of review articles
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Guido Tytgat Profile of Pete Peterson Profile of Peter Cotton Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Antibodies to infliximab influence outcomes and drug levels in IBD

January's issue of the American Journal of Gastroenterology reviews the impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with IBD.

News image

Antibodies to infliximab have been associated with loss of clinical response and lower serum infliximab levels in some studies of patients with inflammatory bowel disease (IBD).

This has important implications for patient management and development of novel biologic therapies.

Dr Kavinderjit Nanda from Massachusetts, USA performed a systematic review and meta-analysis of studies that reported clinical outcomes and infliximab levels according to patients’ Antibodies to infliximab status.

MEDLINE, Web of Science, CINAHL, Scopus, and EMBASE were searched for eligible studies.

The researchers reported quality assessment was undertaken using GRADE criteria.

Raw data from studies meeting inclusion criteria was pooled for meta-analysis of effect estimates.

Sensitivity analysis was performed for all outcomes.

The team of doctors reported that a funnel plot was performed to assess for publication bias.

The team identified 13 studies that met the inclusion criteria, and reported results in 1,378 patients with inflammatory bowel disease.

All included studies had a high risk of bias in at least 1 quality domain.

The team of researchers found that the pooled risk ratio of loss of clinical response to infliximab in patients with IBD who had antibodies to infliximab was 3.2, when compared with patients without antibodies to infliximab.

This effect estimate was predominantly based on data from patients with Crohn's disease.

The doctors found that data only from patients with ulcerative colitis exhibited a non-significant relative risk of loss of response of 2.2 in those with antibodies to infliximab.

The standardized mean difference in trough serum infliximab levels between groups was −0.8
American Journal of Gastroenterology

Heterogeneity existed between studies, in both methods of antibodies to infliximab detection, and clinical outcomes reported.

The team observed that 3 studies reported trough serum infliximab levels according to antibodies to infliximab status.

The standardized mean difference in trough serum infliximab levels between groups was −0.8.

A funnel plot suggested the presence of publication bias.

Dr Nanda's team concludes, "The presence of antibodies to infliximab is associated with a significantly higher risk of loss of clinical response to infliximab and lower serum infliximab levels in patients with inflammatory bowel disease."

"Published studies on this topic lack uniform reporting of outcomes."

"High risk of bias was present in all the included studies."

Am J Gastroenterol 2013; 108:40–47
15 January 2013

Go to top of page Email this page Email this page to a colleague

 29 July 2014

Advanced search
 29 July 2014 
Causes of GI bleeding in cirrhosis
 29 July 2014 
ALT increases in Hep B
 29 July 2014 
Fluticasone in eosinophilic esophagitis
 28 July 2014 
Statins reduce Barrett's
 28 July 2014 
Score predicts risk for Barrett’s esophagus
 28 July 2014 
Gastric cancer prevention
 25 July 2014 
De-escalation of therapy in IBD
 25 July 2014 
Bionic pancreas in type 1 diabetes
 25 July 2014 
Primary care physician counselling and colonoscopy
 24 July 2014 
Diagnostic tool for obscure-overt GI bleeding
 24 July 2014 
Statin use and Barrett’s esophagus
 24 July 2014 
Atopy and functional GI disorders
 23 July 2014 
Sofosbuvir and ribavirin for Hep C
 23 July 2014 
Early corticosteroids after the diagnosis of ulcerative colitis
 23 July 2014 
C-section and IBD risk
 22 July 2014 
Thromboembolism in IBD
 22 July 2014 
Alcohol and colorectal adenoma risk
 22 July 2014 
Cognitive behavioral therapy in IBS
 21 July 2014 
Stents to prevent post-ERCP pancreatitis
 21 July 2014 
Psychometric validation of IBS symptom severity
 21 July 2014 
Mortality in IBD
 18 July 2014 
Treatment of enteropancreatic neuroendocrine tumors
 18 July 2014 
Ulcer complications and dyspeptic symptoms
 18 July 2014 
ERCP with overtube-assisted enteroscopy
 17 July 2014 
Treatment of H. pylori
 17 July 2014 
Ultrasound for diagnosis of gastric varices
 17 July 2014 
Small intestinal permeability in diarrhea predominant IBS
 16 July 2014 
Mortality after colectomy in IBD
 16 July 2014 
Esophageal cancer missed at endoscopy
 16 July 2014 
Screening for Hepatitis B
 15 July 2014 
Diagnosing diverticulitis
 15 July 2014 
Variation in management decisions for colorectal cancer
 15 July 2014 
Muscle cramps in cirrhosis
 14 July 2014 
Predicting the course of ulcerative colitis
 14 July 2014 
Choice in colorectal cancer screening tests
 14 July 2014 
Adhesions in abdominal surgery
 11 July 2014 
Temporal evolution of antidrug antibodies in IBD
 11 July 2014 
Atopy and functional gastrointestinal disorders
 11 July 2014 
Fecal microbiota transplant for C. diff
 10 July 2014 
Acid-suppressive medications and cancer risk in Barrett's
 10 July 2014 
Personalized medicine in the management of IBD
 10 July 2014 
Pregnancy outcome in anti-TNF treated women with IBD
 09 July 2014 
Quality of care provided to patients with varices
 09 July 2014 
Eosinophilic esophagitis and celiac disease
 09 July 2014 
Diagnosis and management of adult celiac disease
 08 July 2014 
Screening for Hep B
 08 July 2014 
NSAID-induced small intestinal injury
 08 July 2014 
Drug-induced liver injury
 07 July 2014 
Obesity and complications after lapaproscopic colorectal surgery
 07 July 2014 
Everolimus and advanced hepatocellular carcinoma
 07 July 2014 
Pediatric celiac disease risk factors
 04 July 2014 
Day-case vs inpatient laparoscopic fundoplication
 04 July 2014 
Alcohol assessment in liver transplant
 04 July 2014 
Clinical competence in colorectal cancer surgery
 03 July 2014 
Predicting acute liver failure in drug-induced liver injury
 03 July 2014 
Cognitive dysfunction impairs quality of life after liver transplant
 03 July 2014 
NOTES for colon resections
 02 July 2014 
Routine colonoscopy for uncomplicated diverticulitis
 02 July 2014 
Risk of stroke in ulcerative colitis
 02 July 2014 
Hemodialysis during liver transplant

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2014 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us